Evidence map›Paper›PMID 28685225›Full record

Trial reportEndocrine2017

Phase II trial of pazopanib in advanced/progressive malignant pheochromocytoma and paraganglioma.

Sina Jasim, Vera J Suman, Camilo Jimenez, Pamela Harris, Kostandinos Sideras, Jill K Burton, Francis Paul Worden, Richard J Auchus, Keith C Bible

Abstract readClinical Trial, Phase IIMulticenter Study
PubMed Publisher
In one paragraph

Trial report in Endocrine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed, 1 pooled it
6.4field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 1 synthesis or guideline pooled it, 59 citations in OpenAlex.

  1. Multidisciplinary practice guidelines for the diagnosis, genetic counseling and treatment of pheochromocytomas and paragangliomas.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2021
    Guideline
  2. Trial
  3. Review
  4. Approach to the Patient With Metastatic Pheochromocytoma and Paraganglioma.The Journal of clinical endocrinology and metabolism · 2025
    Article
  5. Review
  6. Pheochromocytoma in MEN2.Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer · 2025
    Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. New Biology of Pheochromocytoma and Paraganglioma.Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2022
    Review
  14. Targeted Therapies in Pheochromocytoma and Paraganglioma.The Journal of clinical endocrinology and metabolism · 2022
    Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. High-specific-activityFuture oncology (London, England) · 2021
    Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Sina JasimDepartment of Endocrinology, Diabetes, Metabolism, and Nutrition, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA.
Vera J SumanDivision of Biomedical Statistics and Informatics, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA.
Camilo JimenezUniversity of Texas, MD Anderson Cancer Center, 1155 Pressler Street, Houston, TX, 77030, USA.
Pamela HarrisNational Institute of Health (NIH/NCI), 9000 Rockville Pike, Bethesda, MD, 20892, USA.
Kostandinos SiderasDivision of Medical Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA.
Jill K BurtonDivision of Medical Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA.
Francis Paul WordenDivision of Medical Oncology, University of Michigan, 1500 East Medical Center Drive, Ann Arbor, MI, 48109, USA.
Richard J AuchusDivision of Metabolism, Endocrinology and Diabetes, Department of Internal Medicine and Department of Pharmacology, University of Michigan, 1150 West Medical Center Drive, Ann Arbor, MI, 48109, USA.
Keith C BibleDivision of Medical Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA. bible.keith@mayo.edu.
Mayo Clinic · USUniversity of Michigan–Ann Arbor · USNational Institutes of Health · USThe University of Texas MD Anderson Cancer Center · US

Funding

Phase 2 Clinical Trials Program for Experimental Therapeutics Clinical Trials NetworkUM1CA186686 · NCI · MAYO CLINIC ROCHESTER · PI ADJEI, ALEX A. · 2014 to 2019
$5.3M
NCI NIH HHS UM1 CA186686
6 · The paper itself

Abstract

introductionPheochromocytomas and paragangliomas (Pheo/PGL) are rare, vascular, sometimes malignant endocrine tumors. Case reports indicate the activity of vascular endothelium growth factor receptor-targeted kinase inhibitors in these cancers.

objectivesTo assess the antitumor activity and tolerability of pazopanib in progressive malignant Pheo/PGL. PATIENTS AND

methodsThis multicenter Phase II trial (MC107C) enrolled individuals  ≥18 years old with disease progression ≤ 6 months prior to registration, Eastern Cooperative Oncology Group PS 0-2, and measurable disease (response evaluation criteria in solid tumors 1.0). Pazopanib was administered in 28-day cycles, with the regimen ultimately being as follows: cycle 1: 400 mg daily on days 1-14, cycle 2: 800 mg daily on days 1-14, and then cycle 2 + : 800 mg daily on all days.

resultsThe study was halted due to poor accrual. Seven patients were enrolled (05/2011-11/2014). One patient withdrew consent prior to treatment, leaving six evaluable patients. Treatment was discontinued, due to the following reasons: disease progression (4); withdrawal (1); and grade 4 (Takotsubo) cardiomyopathy (1). The median number of cycles administered was 4 (range: 2-29, total: 49). Four patients had >1 dose reduction due to the following reasons: fatigue (1), abnormal liver tests (2), hypertension and (Takotsubo) cardiomyopathy (1), and headaches (1). Common severe (Common Terminology Criteria for Adverse Events v3.0 grades 3-5) toxicities were as follows: hypertension (3/6), (Takotsubo) cardiomyopathy (2/6), diarrhea (1/6), fatigue (1/6), headache (1/6), and hematuria (1/6). One confirmed partial response was observed in PGL (17%, duration 2.4 years); median progression-free survival and overall survival were 6.5 and 14.8 months, respectively.

conclusionPazopanib has activity in Pheo/PGL requiring more study; optimal alpha- and beta-blockade are imperative pre-therapy in patients with secretory tumors, as risk of hypertension and cardiomyopathy are potentially life threatening.

Indexed as

Adrenal Gland NeoplasmsAdultAgedAged, 80 and overAngiogenesis InhibitorsDisease-Free SurvivalElectrocardiographyEndocrine Gland NeoplasmsFemaleHumansIndazolesMaleMiddle AgedParagangliomaPheochromocytomaProtein Kinase InhibitorsAngiogenesis InhibitorsIndazolespazopanibProtein Kinase InhibitorsPyrimidinesReceptors, Vascular Endothelial Growth FactorSulfonamidesMetastaticParagangliomaPazopanibTakotsubo cardiomyopathy

Identifiers

PMID28685225
OpenAlexW2734014749

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.